entertainment -WSS

entertainment

author：hotspot 2025-10-06 08:33:01 - browse：41

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： My daughter's legacy lives on through her writing, phage therapy

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Moderna says combo Covid

Study: Why relieving medical debt did not improve financial outcomes

My daughter's legacy lives on through her writing, phage therapy

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Study: Why relieving medical debt did not improve financial outcomes

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Moonlake's readout produced a cash windfall. Risks remain

What will save rural psychiatry services? Higher Medicaid payments

Sports medicine is finally prioritizing gender equality

Moderna says combo Covid

Malaria cases in Florida and Texas: Here’s what you need to know

Heat waves linked to early deliveries, preterm births in new study

Virginia high school admissions case could be legal follow

How faith leaders like me can help address America's obesity epidemic

Bright Health sells Medicare Advantage business to Molina

Stigma and the return of syphilis

hotspot

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Study: Why relieving medical debt did not improve financial outcomes

California wildfire smoke linked to 52,000 early deaths, study says

Lab trade group sues FDA to halt regulation of lab

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

focus

leisure time

hotspot

focus